A new study published in The Journal of Urology® revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs. Read the article.
Howard Wolinsky a journalist based in the Chicago area, was diagnosed with early prostate cancer in 2010. In part one of a series he described his diagnosis and his decision to chose active surveillance. In the second part, he shared his experience during 5 years of active surveillance and in this part he tells his continuing quest to make the best — and most informed — decision about his care. Howard Wolinsky decides it may all be in the genes. Read the article.
In partnership with Cancer Council Australia and a multi-disciplinary expert advisory panel comprising urologists, medical oncologists, radiation oncologists, pathologists, general practitioners, epidemiologists, allied health professionals and consumers, Prostate Cancer Foundation of Australia has developed national evidence-based clinical practice guidelines on PSA testing and early management of test-detected prostate cancer. Read the article.
A device used to protect American marines from anthrax during the Gulf War is now safeguarding some Canadian men against aggressive prostate cancer thanks to the ingenuity of a London scientist. The device is so precise and quick, in just three or four minutes, using just a teardrop of blood, a doctor can see if a patient has a typical prostate cancer, which grows slowly, or an ominous type that must be treated aggressively. Read the article.
Prostate-specific antigen (PSA)-based screening for prostate cancer has long been controversial. With guidelines changing on a regular basis and experts disagreeing over its use, determining whether or not to get tested can be confusing. Arming yourself with a better understanding of the issues can guide your decision-making process. Read the article.
Prostate cancer survivors are most likely to die from something other than cancer, with cardiovascular disease as the most common cause, according to a new study. Androgen deprivation therapy, or ADT, may increase several cardiovascular risk factors that contribute to heart disease and adverse cardiovascular events, researchers at Vanderbilt University report. Read the article.
The optimal treatment strategy for men with prostate cancer has evolved dramatically, with a growing acceptance of multimodal approaches that include surgery, hormonal therapy, and radiotherapy for patients with high-risk prostate cancer, according to Matthew Cooperberg, MD. Furthermore, in the low-risk population, active surveillance is now being utilized more appropriately and effectively. In an interview with Targeted Oncology, Cooperberg, genitourinary cancer specialist, University of California San Francisco (UCSF), discussed the varying management techniques for both low- and high-risk prostate cancers, including radiation therapy, surgery, hormonal therapy, and active surveillance. Read the article.
Several recent short-term intervention studies failed to show vitamin E supplementation was protective against the development of various cancers, most notably lung and prostate cancer. In fact, in the SELECT study, individuals taking vitamin E supplements showed a 17 percent higher incidence of prostate cancer. A review of the literature suggests while the recent research on vitamin E may be conflicting, evidence supporting the anti-cancer properties of a specific form of vitamin E known as vitamin E succinate (alpha-tocopheryl succinate) is promising. Read the article.